306 related articles for article (PubMed ID: 20442691)
1. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.
Sagreiya H; Berube C; Wen A; Ramakrishnan R; Mir A; Hamilton A; Altman RB
Pharmacogenet Genomics; 2010 Jul; 20(7):407-13. PubMed ID: 20442691
[TBL] [Abstract][Full Text] [Related]
2. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
3. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
5. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
[TBL] [Abstract][Full Text] [Related]
6. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.
Mazzaccara C; Conti V; Liguori R; Simeon V; Toriello M; Severini A; Perricone C; Meccariello A; Meccariello P; Vitale DF; Filippelli A; Sacchetti L
PLoS One; 2013; 8(8):e71505. PubMed ID: 23990957
[TBL] [Abstract][Full Text] [Related]
7. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.
Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH
J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313
[TBL] [Abstract][Full Text] [Related]
8. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
[TBL] [Abstract][Full Text] [Related]
10. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
11. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
12. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
[TBL] [Abstract][Full Text] [Related]
13. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
[TBL] [Abstract][Full Text] [Related]
14. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
15. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
[TBL] [Abstract][Full Text] [Related]
17. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Drozda K; Wong S; Patel SR; Bress AP; Nutescu EA; Kittles RA; Cavallari LH
Pharmacogenet Genomics; 2015 Feb; 25(2):73-81. PubMed ID: 25461246
[TBL] [Abstract][Full Text] [Related]
18. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
[TBL] [Abstract][Full Text] [Related]
19. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
